newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERV
  • Minerva Neurosciences reported financial & business updates for the second quarter ended June 30, 2026.
  • The confirmatory Phase 3 trial (C19) for roluperidone is ongoing with topline efficacy data expected in the second half of 2027.
  • Roluperidone remains the only late-stage drug candidate targeting negative symptoms of schizophrenia.
  • The C19 study will enroll 380 patients across approximately 40 global sites.
  • Phase A evaluates roluperidone 64 mg versus placebo for 12 weeks to assess primary negative symptoms.
  • Phase B evaluates longer-term relapse of positive symptoms over 52 weeks versus common antipsychotics, with data expected in 2H 2028.
  • The Scientific Advisory Board was expanded to eleven members to guide the Phase 3 trial & future pipeline programs.
  • Remy Luthringer, Michael Davidson, & Jonathan Rabinowitz co-authored a 2026 longitudinal analysis of 1,139 CATIE trial patients regarding negative symptom severity.
  • Research & development expenses were $7.2 million for the three months ended June 30, 2026, & $12.4 million for the six months ended June 30, 2026.
  • General & administrative expenses were $3.5 million for the three months ended June 30, 2026, & $14.9 million for the six months ended June 30, 2026.
  • GAAP net income for the three months ended June 30, 2026, was $17.5 million, driven by a $27.6 million non-cash gain on warrant liability.
  • GAAP net loss for the six months ended June 30, 2026, was $107.9 million, reflecting an $81.8 million non-cash loss on warrant liability.
  • Cash, cash equivalents, marketable securities, & restricted cash totaled approximately $75.4 million as of June 30, 2026.
  • Total GAAP liabilities were $296.6 million as of June 30, 2026, compared to $233.8 million as of December 31, 2025.